FDA has granted priority review to bedaquiline, or TMC207 (Johnson & Johnson's Janssen Research & Development), for treatment of multidrug-resistant tuberculosis.
FDA has granted priority review to bedaquiline, or TMC207 (Johnson & Johnson's Janssen Research & Development), for treatment of multidrug-resistant tuberculosis (TB). Bedaquiline would be the first drug specifically indicated for multidrug-resistant TB, and the first new type of TB drug in more than 4 decades.
On June 29, the drug maker applied for approval to market bedaquiline as part of combination therapy for adults with multidrug-resistant TB lung infections.
Under a priority review, FDA aims to decide whether to approve drugs within 6 months of the application's submission, rather than the standard 10 months.
About 1.4 million people worldwide die from TB each year, about 10% of them from forms resistant to at least two of the standard drugs for the deadly bacterial disease.
J&J applied for approval to market the drug in the European Union on Aug. 31.
Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation
April 24th 2024By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.